RG
SLN

Rathbones Group’s Silence Therapeutics SLN Stock Holding History

Rathbones Group’s Portfolio SLN Stock Details SLN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-18,421
Closed -$107K – 662
2025
Q2 		$107K Hold
18,421
– – ﹤0.01% 583
2025
Q1 		$51.9K Hold
18,421
– – ﹤0.01% 579
2024
Q4 		$127K Hold
18,421
– – ﹤0.01% 559
2024
Q3 		$335K Hold
18,421
– – ﹤0.01% 462
2024
Q2 		$350K Sell
18,421
-1,485
-7% -$31.6K ﹤0.01% 463
2024
Q1 		$430K Buy
+19,906
New +$433K ﹤0.01% 434

Other funds holding SLN

TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
LOAMU
Lombard Odier Asset Management (USA) New York $727M AUM 41.88% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
CF
Cantor Fitzgerald New York $9.31B AUM 73.66% 1-Year Est. Return

Rathbones Group's SLN Position: Q3 2025 in Review

Rathbones Group sold out of Silence Therapeutics (SLN) in Q3 2025, closing a stake of 18,421 shares — an estimated $107K sold.

Rathbones Group first reported a position in SLN in Q1 2024 and held it in 6 quarters. The position peaked at $430K in Q1 2024. 54 funds tracked by Wall St. Rank hold SLN as of Q3 2025.

  • Rathbones Group reported no remaining Silence Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Rathbones Group sold 18,421 Silence Therapeutics shares in Q3 2025, an estimated $107K.
  • Rathbones Group first reported a position in Silence Therapeutics in Q1 2024 and held it in 6 quarters.
  • Rathbones Group's Silence Therapeutics position peaked at $430K in Q1 2024.
  • 54 funds tracked by Wall St. Rank held Silence Therapeutics as of Q3 2025.

Based on Rathbones Group's 13F filing for Q3 2025, filed 13 Nov 2025.